FDG-PET prediction of head and neck squamous cell cancer outcomes

Archives of Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 12, 2004, Pages 1361-1367

  Schwartz, David L ^a,b,c   Rajendran, Joseph ^b   Yueh, Bevan ^a   Coltrera, Marc D ^a   LeBlanc, Michael ^a   Eary, Janet ^b   Krohn, Kenneth ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE EVENT HAZARD RATIO; DISEASE FREE SURVIVAL; DRUG UPTAKE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; NONBIOLOGICAL MODEL; OROPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STANDARDIZED UPTAKE VALUE;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; FUCOSE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 10044237790     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.130.12.1361     Document Type: Article

References (30)

1. Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? Cancer. 2004;100:1171-1178.
2. Lydiatt WM, Shah JP, Huffman HT. AJCC stage groupings for head and neck cancer: should we look at alternatives? a report of the Head and Neck Sites Task Force. Head Neck. 2001;23:607-612.
3. Osman I, Sherman E, Singh B, et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol. 2002;20:2980-2987.
4. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003;95:198-205.
5. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356.
6. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58:959-965.
7. Friedlander PL. The use of genetic markers in the clinical care of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2003;129:363-366.
8. Maisey MN. Overview of clinical PET. Br J Radiol. 2002;75(special issue):S1-S5.
9. Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med. 2003;44:24-29.
10. Schechter NR, Gillenwater AM, Byers RM, et al. Can positron emission tomography improve the quality of care for head-and-neck cancer patients? Int J Radiat Oncol Biol Phys. 2001;51:4-9.
11. Schwartz DL, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003;129:1173-1178.
12. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. In press.
13. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer. 1988;62:1074-1078.
14. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer. 1998;82:2227-2234.
15. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292.
16. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149-1154.
17. 18F]fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-1404.
18. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PFJ in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
19. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET: a possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512-516.
20. Brun E, Kjellen E, Tennvall J, et al, FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
21. Kitagawa Y, Sano K, Nishizawa S, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging. 2003;30:63-71.
22. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015-1024.
23. Beaulieu S, Kinahan P, Tseng J, et al. SUV varies with time after injection in (18) F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044-1050.
24. Kalckar HM. 50 Years of biological research: from oxidative phosphorylation to energy requiring transport regulation. Annu Rev Biochem. 1991;60:1-37.
25. Burgman P, O'Donoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001;42:170-175.
26. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of 18 fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
27. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337-1344.
28. Couture C, Raybaud-Diogene H, Tetu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94:713-722.
29. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100:7737-7742.
30. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.